These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1754 related articles for article (PubMed ID: 33161717)

  • 1. Tumor-Targeted Nanomedicine for Immunotherapy.
    Cabral H; Kinoh H; Kataoka K
    Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-functional nanomedicines for combinational cancer immunotherapy that transform cold tumors to hot tumors.
    Cho H; Kim K
    Expert Opin Drug Deliv; 2024 Apr; 21(4):627-638. PubMed ID: 38682272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy.
    Gao J; Wang WQ; Pei Q; Lord MS; Yu HJ
    Acta Pharmacol Sin; 2020 Jul; 41(7):986-994. PubMed ID: 32317755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanomedicines for an Enhanced Immunogenic Cell Death-Based
    Zhao C; Wang C; Shan W; Wang Z; Chen X; Deng H
    Acc Chem Res; 2024 Mar; 57(6):905-918. PubMed ID: 38417027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoscale Metal-Organic Frameworks for Cancer Immunotherapy.
    Ni K; Luo T; Nash GT; Lin W
    Acc Chem Res; 2020 Sep; 53(9):1739-1748. PubMed ID: 32808760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Smart Nanosized Drug Delivery Systems Inducing Immunogenic Cell Death for Combination with Cancer Immunotherapy.
    Zhou L; Zhang P; Wang H; Wang D; Li Y
    Acc Chem Res; 2020 Sep; 53(9):1761-1772. PubMed ID: 32819102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
    Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in nanomedicines for photodynamic therapy (PDT)-driven cancer immunotherapy.
    Ji B; Wei M; Yang B
    Theranostics; 2022; 12(1):434-458. PubMed ID: 34987658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stimuli-Sheddable Nanomedicine Overcoming Pathophysiological Barriers for Potentiating Immunotherapy of Cancer.
    Wang J; Zhou M; Chen F; Liu X; Gao J; Wang W; Wang H; Yu H
    J Biomed Nanotechnol; 2021 Aug; 17(8):1486-1509. PubMed ID: 34544528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanomedicines as enhancers of tumor immunogenicity to augment cancer immunotherapy.
    Dogheim GM; El Feel NE; Abd El-Maksod EA; Amer SS; El-Gizawy SA; Abd Elhamid AS; Elzoghby AO
    Drug Discov Today; 2024 Mar; 29(3):103905. PubMed ID: 38295898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fe(III)-Shikonin supramolecular nanomedicines as immunogenic cell death stimulants and multifunctional immunoadjuvants for tumor vaccination.
    Feng W; Shi W; Cui Y; Xu J; Liu S; Gao H; Zhu S; Liu Y; Zhang H
    Theranostics; 2023; 13(15):5266-5289. PubMed ID: 37908730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasmon-Driven Catalytic Chemotherapy Augments Cancer Immunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway.
    Ding Y; Sun Z; Gao Y; Zhang S; Yang C; Qian Z; Jin L; Zhang J; Zeng C; Mao Z; Wang W
    Adv Mater; 2021 Aug; 33(34):e2102188. PubMed ID: 34278622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges.
    Martin JD; Cabral H; Stylianopoulos T; Jain RK
    Nat Rev Clin Oncol; 2020 Apr; 17(4):251-266. PubMed ID: 32034288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remodeling tumor microenvironment with nanomedicines.
    Martin JD; Miyazaki T; Cabral H
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Nov; 13(6):e1730. PubMed ID: 34124849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
    Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
    J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanomedicines for reversing immunosuppressive microenvironment of hepatocellular carcinoma.
    Pan X; Ni S; Hu K
    Biomaterials; 2024 Apr; 306():122481. PubMed ID: 38286109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors.
    Qi J; Jin F; Xu X; Du Y
    Int J Nanomedicine; 2021; 16():1435-1456. PubMed ID: 33654395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salicylic acid-based hypoxia-responsive chemodynamic nanomedicines boost antitumor immunotherapy by modulating immunosuppressive tumor microenvironment.
    Sun K; Yu J; Hu J; Chen J; Song J; Chen Z; Cai Z; Lu Z; Zhang L; Wang Z
    Acta Biomater; 2022 Aug; 148():230-243. PubMed ID: 35724919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor Abnormality-Oriented Nanomedicine Design.
    Zhou Q; Xiang J; Qiu N; Wang Y; Piao Y; Shao S; Tang J; Zhou Z; Shen Y
    Chem Rev; 2023 Sep; 123(18):10920-10989. PubMed ID: 37713432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 88.